We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

31 hedge funds and large institutions have $27.5M invested in Xenon Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

3.48% less ownership

Funds ownership: 55.27% → 51.79% (-3.5%)

12% less capital invested

Capital invested by funds: $31.3M → $27.5M (-$3.84M)

21% less funds holding

Funds holding: 39 → 31 (-8)

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

Holders
31
Holders Change
-8
Holders Change %
-20.51%
% of All Funds
0.77%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
2
Increased
6
Reduced
5
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SSA
Schonfeld Strategic Advisors
New York
+$464K
2
Deutsche Bank
Deutsche Bank
Germany
+$306K
3
BI
BVF Inc
California
+$217K
4
DMK
David M. Knott
+$139K
5
Renaissance Technologies
Renaissance Technologies
New York
+$80.7K

Top Sellers

1
PA
Perceptive Advisors
New York
-$2.28M
2
NHAS
Novo Holdings A/S
Denmark
-$402K
3
Morgan Stanley
Morgan Stanley
New York
-$259K
4
WMSA
Weiss Multi-Strategy Advisers
New York
-$99K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$61K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$10.6M +$217K +70,000 +2%
Capital World Investors
2
Capital World Investors
California
$4.22M – – –
O
3
OrbiMed
New York
$1.87M – – –
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$1.32M +$24.8K +8,024 +2%
DCM
5
DAFNA Capital Management
California
$1.11M – – –
IPC
6
Invesco Private Capital
New York
$1.11M – – –
TCM
7
Tekla Capital Management
Massachusetts
$1.03M – – –
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$915K – – –
SM
9
Sabby Management
Florida
$907K -$9.93K -3,208 -1%
SSA
10
Schonfeld Strategic Advisors
New York
$811K +$464K +150,000 +120%
SFM
11
Sphera Funds Management
Israel
$673K – – –
KPF
12
K2 Principal Fund
Ontario, Canada
$485K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$461K +$80.7K +26,100 +20%
AG
14
Artal Group
Luxembourg
$443K – – –
Deutsche Bank
15
Deutsche Bank
Germany
$323K +$306K +98,859 +924%
JGC
16
J. Goldman & Co
New York
$214K – – –
State of New Jersey Common Pension Fund D
17
State of New Jersey Common Pension Fund D
New Jersey
$192K – – –
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$162K – – –
SC
19
Scotia Capital
Ontario, Canada
$160K +$58K +18,742 +53%
DMK
20
David M. Knott
$133K +$139K +45,000 New
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$121K -$46.4K -15,000 -27%
Stifel Financial
22
Stifel Financial
Missouri
$65K +$67.1K +21,700 New
NSEDCP
23
NJ State Employees Deferred Compensation Plan
New Jersey
$59K – – –
LWIC
24
Leith Wheeler Investment Counsel
British Columbia, Canada
$47K – – –
JP Morgan Chase
25
JP Morgan Chase
New York
$27K -$4.92K -1,590 -15%
1
2

XENE Hedge Fund Activity: Q3 2017 in Review

31 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2017, worth a combined $27.5M — down 12% from $31.3M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of XENE and 2 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 6 added.

The largest buyer was Schonfeld Strategic Advisors, adding an estimated $464K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.28M sold.

  • 31 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2017, down from 39 in Q2 2017.
  • Funds reported $27.5M of Xenon Pharmaceuticals stock for Q3 2017, down 12% quarter-over-quarter.
  • 2 funds opened new Xenon Pharmaceuticals positions in Q3 2017 and 9 closed out, a net change of -7 holders.
  • The largest Xenon Pharmaceuticals buyer in Q3 2017 was Schonfeld Strategic Advisors, an estimated $464K added.
  • The largest Xenon Pharmaceuticals seller in Q3 2017 was Perceptive Advisors, an estimated $2.28M sold.

Based on aggregated 13F filings for Q3 2017.